Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

106.15 -0.23 (-0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
57 58 Next >
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise. 
Via InvestorPlace
Key Takeaways From Gilead Sciences Analyst Ratings
Via Benzinga
3 Magnificent Stocks Retirees Can Buy and Hold Forever
These stocks could be ideal for investors in their golden years. 
Via The Motley Fool
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Via Benzinga
What 8 Analyst Ratings Have To Say About Gilead Sciences
Via Benzinga
7 Dividend Stocks to Buy Now: June 2024
These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands. 
Via InvestorPlace
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKNG (+9.69%), DELL (+8.19%), ADSK (+7.99%), and GFI (+7.15%). 
Via Benzinga
MarketBeat Week in Review – 6/17 - 6/21
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Top Analyst Reports For Abbott, BP & Gilead
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, BP p.l.c.and Gilead Sciences, Inc., as well as two micro-cap stocks Smith-Midland Corp. and... 
Via Talk Markets
Nvidia Snaps 8-Week Winning Run, S&P 500 Marks Longest Streak Without A 2% Drop Since Great Recession, Oil Prices Stage Comeback: This Week In The Market
Stock market rally continues with new highs in S&P 500 and Nasdaq 100, driven by tech and semiconductor sectors, but concerns arise over lack of broad participation and high concentration in mega-cap... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
Why Gilead Sciences Stock Is Trading Higher Friday
On Thursday before the market opened, Gilead announced efficacy data for its possible HIV prevention drug, Lenacapavir. 
Via Benzinga
Pre-Market Movers - June 21, 2024
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers. 
Via Talk Markets
Gilead Sciences Stock Surges on HIV Treatment Trial Success
Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. 
Via MarketBeat
Exposures Product Safety
Defying the Norms: 3 High P/E Stocks With Room to Run
Gilead Sciences, Crowdstrike and DataDog might be the best high P/E stocks to buy, offering substantial growth despite elevated valuations. 
Via InvestorPlace
S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday?
After the Juneteenth holiday break, Wall Street reopened with a cautious tone, as the S&P 500 and Nasdaq 100 indices declined after hitting all-time highs around midday trading in New York. This... 
Via Benzinga
Topics Stocks
Exposures US Equities
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
The company tested its HIV prevention drug in cisgender women in Uganda and South Africa. 
Via Investor's Business Daily
Why Is Gilead Sciences Stock Trading Higher On Thursday?
Gilead Sciences announced its Phase 3 PURPOSE 1 trial results showing 100% efficacy of twice-yearly injectable lenacapavir in preventing HIV-1 in cisgender women. The trial met key efficacy endpoints,... 
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment. 
Via Investor's Business Daily
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with magrolimab. 
Via Benzinga
Topics Death
Exposures Death
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug. 
Via Investor's Business Daily
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.